In immunohistochemistry (IHC), progesteron receptor (PR) is used to determine prognosis in breast cancer. The American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) recommends that the PR status of patients is determined on all invasive breast cancers and breast cancer recurrences [1]. It is recommended that the PR status of the tumor is considered positive if there are at least 1 % positive tumor nuclei in a tissue sample.
The APP work fully automated in an integrated setting, from detecting the patient tissue to exporting the relevant outputs.